Weekly Research Update | 12–19 October 2026
Research published this week highlights three important aspects of aspergillosis care: developing faster diagnostic tests, preventing fungal infections in vulnerable patients, and understanding how hospital ventilation may influence exposure to Aspergillus.
Although these studies focus mainly on invasive aspergillosis rather than chronic pulmonary aspergillosis (CPA) or allergic bronchopulmonary aspergillosis (ABPA), they provide useful insights into how fungal infections are detected and prevented.
1. Can a rapid blood test help detect Aspergillus infection?
Diagnosing invasive aspergillosis can be difficult, particularly in people whose immune systems are weakened by illness or medical treatment. Doctors often use several investigations, including CT scans, fungal cultures and blood tests.
One commonly used test detects galactomannan, a substance released by Aspergillus fungi.
Researchers in Pakistan investigated whether a rapid lateral-flow test could provide useful results compared with a conventional laboratory galactomannan test.
The study examined 155 blood samples using both methods.
What did the researchers find?
- The rapid test detected approximately 78% of samples that were positive using the laboratory test.
- It correctly identified approximately 83% of samples that were negative using the laboratory test.
- Some positive results from the rapid test were not confirmed by the conventional method.
The researchers concluded that the rapid test could be useful for screening, although positive results may need confirmation.
What does this mean for patients?
Faster testing could potentially help doctors investigate suspected fungal infections more promptly, especially where access to specialist laboratories is limited.
However, a negative rapid test cannot completely rule out aspergillosis, and a positive result does not necessarily mean that someone has an active fungal infection.
Doctors must interpret results alongside symptoms, scans, other laboratory findings and the patient’s individual risk factors.
This was a relatively small study, currently available as a preprint, and it compared two tests rather than establishing how accurately the rapid test diagnoses confirmed invasive aspergillosis.
Research: Zaheer F et al. Diagnostic Accuracy of Aspergillus Lateral Flow Assay for Detection of Galactomannan Antigen in Serum. Access Microbiology, 2026.
2. Why do some patients develop fungal infections despite preventive treatment?
People undergoing organ transplantation often receive medicines that suppress their immune systems to prevent rejection of the transplanted organ.
Unfortunately, this also increases their vulnerability to certain infections, including invasive aspergillosis.
Doctors sometimes prescribe antifungal medicines as a precaution, particularly for patients considered at high risk.
A new Italian study examined fungal infections among 286 liver-transplant recipients.
Of these, 85 were classified as high risk and received planned preventive treatment with an echinocandin antifungal, usually caspofungin.
What did the researchers find?
- Eight of the 85 high-risk patients (9.4%) developed an invasive fungal infection within 30 days of transplantation.
- Four of the 201 other recipients (2.0%) developed an invasive fungal infection.
- Most infections in the high-risk group occurred despite preventive treatment and involved mould fungi.
The researchers also examined aspergillosis cases across a longer period. They found no clear evidence of a sustained outbreak associated with a common environmental source.
What does this mean for patients?
Preventive antifungal medicines can be an important part of protecting vulnerable patients, but they cannot eliminate every risk.
Different antifungal medicines work against different fungi, and some infections may develop despite appropriate precautions.
Importantly, the patients receiving preventive treatment were already considered at greater risk. The higher infection rate in this group does not mean that preventive treatment caused infections or was necessarily ineffective.
The findings reinforce the importance of continued monitoring and prompt investigation when symptoms suggest a possible fungal infection.
Research: Viero G et al. Early Invasive Fungal Infections in Liver Transplant Recipients Receiving Risk-Stratified Echinocandin Prophylaxis. Transplant Infectious Disease, 2026.
3. Could hospital ventilation affect the risk of aspergillosis?
Aspergillus spores are widespread in the environment, including in outdoor air, soil and decaying vegetation.
Most people inhale these spores without developing illness. However, people with severely weakened immune systems may be particularly vulnerable.
Hospitals therefore pay close attention to air filtration, ventilation and infection prevention in areas caring for high-risk patients.
A recent scientific commentary in Critical Care examined an important question: does the way intensive care rooms are ventilated influence the risk of pulmonary aspergillosis?
The authors discussed research involving negative-pressure rooms, which are designed to prevent potentially infectious air from escaping into surrounding areas.
They highlighted that findings from different studies have not always been consistent.
One possible explanation is that purpose-built negative-pressure rooms may behave differently from ordinary rooms converted to negative pressure, particularly if airflow and filtration are not carefully managed.
The authors also raised questions about differences in fungal testing between patient groups, which could influence reported infection rates.
What does this mean for patients?
Hospital ventilation is an important part of infection prevention, but simply describing a room as having negative or positive pressure does not tell us everything about its safety.
Airflow direction, filtration, maintenance and the needs of individual patients all matter.
For example, negative-pressure rooms are commonly used to contain airborne infections, while specialised positive-pressure environments with filtered air may be used to protect particularly vulnerable patients from environmental contamination.
This commentary does not establish that negative-pressure rooms cause aspergillosis. Instead, it highlights why careful ventilation design and appropriate infection-control measures are important.
Research: Ichai P et al. Negative-pressure ICU rooms and pulmonary aspergillosis: room conversion matters. Critical Care, 2026.
Other research published this week
Aspergillosis affecting Meckel’s cave
Researchers described a rare infection involving Meckel’s cave, a region near the base of the skull associated with the trigeminal nerve, which carries sensation from the face.
The case illustrates how aspergillosis can occasionally affect structures outside the lungs and may require specialised surgery alongside antifungal treatment.
Aspergillus and tuberculosis infection after kidney transplantation
Another report described the challenges of treating a patient with both Aspergillus infection and tuberculosis following kidney transplantation.
Such cases can be particularly complicated because immunosuppressive medicines, antifungal treatments and tuberculosis drugs may interact.
These are individual case reports, so their findings cannot necessarily be applied to other patients.
What can we take away from this week’s research?
Three themes emerge from these publications.
Diagnosis is improving, but no single test provides every answer. Rapid tests may help clinicians investigate suspected aspergillosis, but results must be interpreted alongside other evidence.
Prevention remains essential for vulnerable patients. Antifungal prophylaxis can be valuable, but continued monitoring is important because breakthrough infections can occur.
The hospital environment matters. Ventilation, air filtration and infection-control practices are important considerations, particularly for people at high risk of invasive fungal infection.
For people living with CPA or ABPA, these studies do not suggest an immediate change to established treatment. Nevertheless, they contribute to a broader understanding of how Aspergillus infections are recognised, prevented and managed.
This article is part of the National Aspergillosis Centre’s weekly research updates, explaining recent scientific publications in language accessible to patients and their families. Research findings should not be used to change treatment without advice from the healthcare team responsible for your care.
Did this page help you?
Tell us in one minute